-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo Therapeutics appoints Laura Sepp-Lorenzino to board

PUBT·04/30/2026 11:05:39
Listen to the news
Lexeo Therapeutics appoints Laura Sepp-Lorenzino to board
  • Lexeo Therapeutics appointed Laura Sepp-Lorenzino to board on April 28, 2026.
  • Board named Sepp-Lorenzino to Science and Technology Committee.
  • Sepp-Lorenzino will serve as director through 2028 annual meeting of stockholders.
  • She has served as principal of genomic medicine consultancy GNMmeds since January 2025.
  • Sepp-Lorenzino previously served as executive vice president, chief scientific officer at Intellia Therapeutics from May 2019 to January 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-193927), on April 30, 2026, and is solely responsible for the information contained therein.